Nasdaq · Healthcare

X4 Pharmaceuticals, Inc (XFOR)

As-reported financials and recent SEC filings for X4 Pharmaceuticals, Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$35.1M

Net income

$-79.2M

Net margin

—

Diluted EPS

$-1.87

ROE

-42.5%

P/E (TTM)

—

Market cap

—

Debt / equity

0.4×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$35.1M	$2.6M	$0	$0	$0
Gross profit	$29.4M	$1.8M	—	—	—
Operating income	$-86.9M	$-36.4M	$-107.5M	$-87.6M	$-85.1M
Net income	$-79.2M	$-37.5M	$-101.2M	$-93.9M	$-88.7M
Diluted EPS	$-1.87	$-0.93	$-2.85	$-2.79	$-3.66

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-01

42026-07-01

32026-07-01

8-K2026-07-01

SCHEDULE 13G/A2026-05-15

EFFECT2026-05-14

8-K/A2026-05-13

42026-05-13

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on XFOR

Search X4 Pharmaceuticals, Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.